Search Clinical Trials
Parent Therapeutic Areas: Oncology

Lung Cancer

Alabama

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Muscle Shoals : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Alaska

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Arizona

Peoria : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Scottsdale : Mayo Clinic

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Tuscan : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Arkansas

Little Rock : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

California

Corona : Compassionate Cancer Care Medical Group

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Duarte : City of Hope

A Phase 2, Open Label, Two Arm Trial to Evaluate the Efficacy of PF-00299804 in Patients with Advanced NSCLC After Failure of at Least One Prior Chemotherapy Regimen and Failure of Treatment with Erlotinib

Duarte : City of Hope

A Phase I Study of MM-10-001 In Advanced Non Small Lung Cancer

Duarte : City of Hope

A Phase I Trial of External Beam Radiotherapy Combined with Carboplatin and Paclitaxel Followed by Radioimmunotherapy (Y-90-Mx-DTPA-cT84.66) in Unresectable or Medically Inoperable Non-Metastatic CEA-Producing Stage III or IIB Non Small Cell Lung Cancer

Duarte : City of Hope

A Randomized, Placebo-Controlled Phase II Clinical Trial of Combination Erlotinib (Tarceva) and and Celecoxib (Celebrex) versus Erlotinib (Tarceva)/Placebo in Advanced Non-Small Cell Lung Cancer Patients

Duarte : City of Hope

FORTIS-C: A Phase 3, Randomzied, Placebo-Controlled Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel as First-Line Therapy in Patients with Locally Advanced or Metastatic Non-Small Lung Cancer

Duarte : City of Hope

GEM017: A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide With or Without Obatoclax Administered Every 3 Weeks to Patients with Extensive-Stage Small Cell Lung Cancer

Duarte : City of Hope

Phase 3 Study of Pemetrexed, Cisplatin and Radiotherapy followed by Consolidation Pemetrexed v Etoposide, Cisplatin and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III NSCLC Other than Predominantly Squamous Cell Histology

Duarte : City of Hope

PHII-65 NCI #7103: A Phase II Study of AZD2171 (NSC #732208)in Patients with Malignant Mesothelioma

Duarte : City of Hope

The Relationship Between Coping, Gender and Psychological Adaptation in People with Lung Cancer

Fountain Valley : Compassionate Cancer Care Medical Group, Inc.

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Fresno : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

La Mesa : Cancer Center Oncology Medical Group

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

La Verne : Wilshire Oncology Medical Group, Inc.

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

La Verne : Accelerated Community Oncology Research Network, Inc. (ACORN)

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Los Angeles : UCLA

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Los Angeles : The Angeles Clinic & Research Institute

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Los Angeles : Kenmar Research Institute, Llc

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Los Angeles : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Los Angeles : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Portland : Providence Portland Medical Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Riverside : Compassionate Cancer Care Medical Group

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

San Diego : University of California San Diego Medical Center

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

San Francisco : Melanoma Center At St. Francis Memorial Hospital

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Colorado

Aurora : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Denver : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Denver : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Connecticut

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Delaware

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Florida

Boynton Beach : Hematology & Medical Oncology

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Hialeah : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Miami : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Ocala : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Orange Park : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Orlando : M D Anderson Cancer Center- Orlando

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Pensacola : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Tampa : Moffitt Cancer Center

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Georgia

Savannah : Memorial Health University Medical Center

Sunitinib, Cisplatin or Carboplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer CALGB 30504

Atlanta : Georgia Cancer Specialists

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Augusta : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Savannah : Memorial Health University Medical Center New!

Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer SWOG S0424

Savannah : Memorial Health University Medical Center

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Savannah : Memorial Health University Medical Center

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Savannah : Memorial Health University Medical Center

Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Savannah : Memorial Health University Medical Center

Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide CALGB 30610

Idaho

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Illinois

Chicago : University Of Chicago Medical Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Hines : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Joliet : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Naperville : Hematology Oncology Consultants, Ltd.

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Niles : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Park Ridge : Oncology Specialists, S.C.

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Peoria : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Quincy : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Indiana

Beech Grove : St. Francis Hospital and Health Centers

Phase 1, Dose Escalation Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

Beech Grove : St. Francis Hospital and Health Centers

Randomized, Multi-Center, Open-Label, Study of Docetaxel Versus Docetaxel/PR104 in Non-Small Cell Lung Cancer (NSCLC)

Beech Grove : St. Francis Hospital and Health Centers

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC)

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Greenfield : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

New Albany : Cancer Care Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Iowa

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Kansas

Overland Park : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Wichita : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Kentucky

Hazard : Kentucky Cancer Clinic

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Lexington : University of Kentucky Chandler Medical Center

Cancer: Lung Cancer Patients Needed for Research Study

Lexington : University of Kentucky Chandler Medical Center

Cancer: Non-small Cell Lung Cancer Research Study

Lexington : University of Kentucky Chandler Medical Center

Cancer: Stage II or III non-small Cell Lung Cancer Research Study

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Maine

Scarborough : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Maryland

Baltimore : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Bethesda : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Hagerstown : The Cancer Center For Clinical Research

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Westminster : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Massachusetts

Boston : Brigham and Women's Hospital

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Burlington : Lahey Clinic

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Michigan

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Flint : Genesys Hurley Cancer Institute

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Kalamazoo : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Southgate : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Minnesota

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Minneapolis : The Cancer Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Minneapolis : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Mississippi

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Pascagoula : The Regional Cancer Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Missouri

Columbia : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Saint Louis : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

St. Joseph : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

St. Louis : Washington University School Of Medicine

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Nevada

Las Vegas : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

New Hampshire

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Lebanon : Norris Cotton Cancer Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

New Jersey

Morristown : Atlantic Health System

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)

Newark : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Vorhees : Virtua Health

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

New Mexico

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

New York

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

East Setauket : North Shore Hematology/Oncology Associates, P.C.

A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux®) in Combination with Platinum-Based Chemotherapy as First Line Treatment of Patients with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

East Syracuse : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Jamaica : Biomedical Research Alliance of New York

Pemetrexed in subjects with Stage III/IV NSCLC

Lake Success : Biomedical Research Alliance of New York

Combination Drug Therapy for non-small cell lung cancer not previously treated with chemotherapy

Lake Success : Biomedical Research Alliance of New York

Non-Small Cell Lung Cancer - Adults

Latham : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Mineola : Winthrop University Hospital Oncology Hematology Division

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

New York : Memorial Sloan Kettering Cancer Center

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

New York : Cornell University

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Poughkeepsie : Vassar Brothers Medical Center

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4.0 cm) - IIIA Non Small Cell Lung Cancer (NSCLC)

Rochester : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Syracuse : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

North Carolina

Chapel Hill : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Durham : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Raleigh : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Winston-Salem : Wake Forest University Comprehensive Cancer Center

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Winston-Salem : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Ohio

Canton : N. Canton Medical Clinic Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Canton : Gabrail Cancer Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Canton : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Columbus : Hematology Oncology Consultants, Inc

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Kettering : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Sylvania : Flower Hospital Cancer Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Oklahoma

Oklahoma City : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Tulsa : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Oregon

Eugene : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Pennsylvania

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Kingston : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Langhorne : St. Mary Medical Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Philadelphia : Fox Chase Cancer Center

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Philadelphia : Merck

An Open Label, Randomized Phase I/IIa Trial Evaluating MK0646 in Combination With Erlotinib for Patients With Recurrent Non-Small Cell Lung Cancer

Philadelphia : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Pittsburgh : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Sayre : Guthrie Foundation For Education And Research

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Rhode Island

Providence : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

South Carolina

Columbia : Wjb Va Medical Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Greenville : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Tennessee

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Memphis : The West Cancer Clinic

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Nashville : Merck

An Open Label, Randomized Phase I/IIa Trial Evaluating MK0646 in Combination With Erlotinib for Patients With Recurrent Non-Small Cell Lung Cancer

Nashville : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Texas

Amarillo : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Corpus Christi : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Dallas : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Dallas : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Houston : The Methodist Hospital Research Institute

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Houston : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplaston A10 And AS2-1 Capsules In Patients With Non Small Cell Lung Cancer

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Adenocarcinoma Of The Lung

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Bronchial Alveolar Carcinoma Of The Lung

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Large Cell, Undifferentiated Or Poorly Differentiated Carcinoma Of The Lung

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Small Cell Carcinoma Of The Lung

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Squamous Cell Carcinoma Of The Lung

Lubbock : Southwest Cancer Treatment And Research Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Odessa : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Wichita Falls : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Utah

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Salt Lake City : Huntsman Cancer Institute At The Univ. Of Utah

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Virginia

Charlottesville : University of Virginia New!

Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer.

Charlottesville : University of Virginia New!

Patients with lung cancer needed for clinical study.

Charlottesville : University of Virginia New!

Patients with lung cancer wanted for clinical trial

Charlottesville : University of Virginia

Phase III randomized multi-standard trial of Gemcitabin in combination with Carboplatin or Paclitaxel vs. Paclitaxel plus Carboplatin in patients with metastatic (stage IIIB pleural effusion or IV) non-small cell lung cancer. HIC #8775

Charlottesville : University of Virginia

Phase III trial of Carboplatin/Paclitaxel and thoracic radiation with or without Thalidomide in patients with stage III non-small cell lung cancer. HIC #8779

Fairfax : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Norfolk : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Roanoke : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Washington

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Seattle : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Vancouver : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Washington, DC

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

West Virginia

Morgantown : West Virginia University - Clinical Trials Research Unit

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with Erlotinib in Non-Small Cell Lung Cancer Patients (APRiCOT-L)

Various Cities : Research Center New!

Lung Cancer Study CASA404A2302

Wisconsin

Diverse Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Weston : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Argentina

Buenos Aires : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Buenos Aires : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Córdova : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Córdova : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Santa Fe : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Santa Fe : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Australia

Camperdown, New South Wales : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Camperdown, New South Wales : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Chermside, Queensland : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Chermside, Queensland : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Fitzroy, Victoria : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Fitzroy, Victoria : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Garran - ACT : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Garran - ACT : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Heidelberg, Victoria : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Heidelberg, Victoria : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Hobart, Tasmania : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Hobart, Tasmania : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Nedlands, Western Australia : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Nedlands, Western Australia : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Perth, Western Australia : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Perth, Western Australia : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Richmond , Victoria : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Richmond , Victoria : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

South Brisbane, Queensland : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

South Brisbane, Queensland : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

South Granville : Merck Sharp & Dohme (Australia) Pty Ltd.

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Tweed Heads, New South Wales : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Tweed Heads, New South Wales : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Waratah , New South Wales : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Waratah , New South Wales : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Austria

Graz : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Graz : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Linz : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Linz : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Vienna : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Vienna : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Wels : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Wels : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Wels : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Wien : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Belgium

Atwerpen : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Atwerpen : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Brussel : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Brussels : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Brussels : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Charleroi : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Charleroi : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Charleroi : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Duffel : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Duffel : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Edegem : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Edgem : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Edgem : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Hasselt : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Hasselt : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Jette : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Jette : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Leuven : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Leuven : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Leuven : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Liège : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Liège : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Liège : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Brazil

Barretos, Sao Paulo : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Barretos, Sao Paulo : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Belo Horizonte, Minas Gerias : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Belo Horizonte, Minas Gerias : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Porto Alegre, Rio Grande Do Sul : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Porto Alegre, Rio Grande Do Sul : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Rio De Janeiro, Rio De Janeiro : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Rio De Janeiro, Rio De Janeiro : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Bulgaria

Plovdiv : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Sofia : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Varna : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Canada

Calgary, Alberta : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Calgary, Alberta : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Edmonton : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Edmonton : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Halifax, Nova Scotia : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Halifax, Nova Scotia : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

London, British Columbia : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

London, Ontario : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

London, Ontario : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Québec, Montreal : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Québec, Montreal : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

St Catharines, Ontario : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

St Catharines, Ontario : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Surrey, British Columbia : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Toronto, ON : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Toronto, Ontario : Toronto General Hospital

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Weston, ON : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Czech Republic

Brno : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Brno : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Ostrava - Poruba : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Plzen : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Plzen : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Praha 4 : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Praha 5 : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Praha 5 : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Praha 5 : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Praha 8 : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Praha 8 : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Praha 8 : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Usti nad Labem : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Usti nad Labem : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Ústí nad Labem : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Denmark

Herlev : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

København Ø : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Odense C : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Estonia

Tallinn : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Tallinn : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Tartu : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Tartu : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Various Cities : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Various Cities : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Finland

Helsinki : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Helsinki : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Oulu : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Oulu : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Tampere : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Tampere : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Turku : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Turku : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

France

Bayonne : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Bayonne : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Beauvais : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Beauvais : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Belfort : Hopital General De Belfort

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Bethune : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Bethune : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Caen : Centre Francois Baclesse

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Caen : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Caen : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Elbeuf : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Elbeuf : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Lille : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Lille : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Limoges : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Limoges : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Lyon : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Lyon : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Marseille : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Marseille : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Marseille Cedex 9 : Hopital Sainte Marguerite

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Meaux : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Meaux : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Metz : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Metz : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Montpellier : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Montpellier : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Mulhouse : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Mulhouse : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Nantes : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Nantes : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Nantes-Saint Herblain Cedex : Clcc Nantes Atlantique

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Nice : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Nice : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Nîmes : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Nîmes : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Paris : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Paris : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Pessac : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Pessac : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Reims : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Reims : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Rennes : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Rennes : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Rennes Cedex 9 : Chu Pontchaillou - Service Pneumologie

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Rouen : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Rouen : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Saint Herblain : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Saint Herblain : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Saint-Priest en Jarez : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Saint-Priest en Jarez : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Saint-Quentin : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Saint-Quentin : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

St Grégoire : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

St Grégoire : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Strasbourg : Hopital Lyautey

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Toulon : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Toulon : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Toulouse : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Toulouse : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Vannes : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Vannes : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Villefranche sur Saône : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Villefranche sur Saône : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Germany

Augsburg : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Augsburg : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Bad Berka : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Bad Berka : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Bad Berka : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Bayreuth : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Bayreuth : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Berlin : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Berlin : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Berlin : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Bielefeld : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Bielefeld : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Bonn : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Bonn : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Ebensfeld : Bezirksklinikum Obermain

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Ebensfeld : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Ebensfeld : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Essen : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Essen : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Essen : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Frankfurt : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Frankfurt : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Frankfurt/Oder : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Frankfurt/Oder : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Freiburg : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Freiburg : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Gauting : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Gauting : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Gauting : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Greifswald : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Greifswald : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Grosshansdorf : Krankenhaus Grosshansdorf

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Grosshansdorf : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Grosshansdorf : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Großhansdorf : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Halle : Krankenhaus Martha-Maria Halle-Doelau Ggmbh

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Halle : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Halle : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Halle (Saale) : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Hamburg : Asklepios Klinik Harburg

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Hamburg : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Hamburg : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Hannover : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Hannover : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Heidelberg : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Heidelberg : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Heidelberg : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Hemer : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Hemer : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Herne : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Herne : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Homburg : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Homburg : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Immenhausen : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Immenhausen : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Karlsruhe : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Koblenz : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Koblenz : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Koeln : Lungenklinik Koeln-Merheim

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Koeln : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Koeln : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Leipzig : Universitaetsklinikum Leipzig

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Leipzig : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Leipzig : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Leipzig : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Leipzig : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Mainz : Klinikum Der Johannes-Gutenberg-Universitaet

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Mainz : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Mannheim : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Minden : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Minden : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Moers : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Moers : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Muelheim : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Muelheim : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Muenchen : Klinikum Rechts Der Isar Der Tum

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Muenchen : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Muenchen : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Muenster : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Muenster : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Oberhausen : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Oberhausen : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Ostercappeln : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Ostercappeln : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Porta Westfalica : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Porta Westfalica : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Regensburg : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Regensburg : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Rosenheim : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Rosenheim : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Troisdorf : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Troisdorf : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Velbert : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Velbert : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Wangen : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Wangen : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Wuerzburg : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Wuerzburg : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Greece

Athens : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Athens : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Chania : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Chania : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Heraklion, Crete : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Heraklion, Crete : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Marousi : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Marousi : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Neo Faliro : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Neo Faliro : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Patra : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Patra : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Piraeus : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Piraeus : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Thessaloniki : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Thessaloniki : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Greensfield Park

Greensfield Park, Greensfield Park : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Greensfield Park, Greensfield Park : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Hong Kong

Kowloon : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Kowloon : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

N.T. : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

N.T. : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Hungary

Budapest : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Budapest : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Budapest : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Budapest : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Debrecen : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Deszk : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Deszk : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Gy¿r : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Gy¿r : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Gyula : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Gyula : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Mátraháza : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Mátraháza : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Mátraháza : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Miskolc : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Miskolc : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Nyíregyháza : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Nyíregyháza : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Pecs : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Skekesfehervar : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Skekesfehervar : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Sopron : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Szombathely : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Szombathely : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Zalaegerszeg-Pozva : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Zalaegerszeg-Pozva : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

India

Ahemdabad : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Ahemdabad : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Hyderabad : Nizam'S Institute Of Medical Sciences

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Hyderabad, Andhra Pradesh : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Hyderabad, Andhra Pradesh : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Manipal, Karnataka : Shirdi Sai Baba Cancer Hospital, Kmc

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Mumbai : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Mumbai : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Navrangpura, Ahmedabad, Gujarat : Vedanta Near Samved Hospital

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Thiruvananthapuram : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Thiruvananthapuram : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Trivandrum, Kerala : Regional Cancer Institute

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Vellore : Christian Medical College

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Ireland

Dublin : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Dublin : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Galway : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Galway : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Israel

Beer-Sheva : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Beer-Sheva : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Haifa : Rambam Medical Center - Pain Palliaton Unit

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Haifa : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Haifa : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Kfar Saba : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Kfar Saba : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Ramat Gan : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Ramat Gan : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Tel Hashomer : Sheba Medical Center

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Italy

Genova : Istituto Nazionale Per La Ricerca Sul Cancro

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Genova : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Genova : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Legnago (VR) : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Legnago (VR) : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Meldola : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Meldola : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Milano : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Milano : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Modena : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Monserrato : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Monserrato : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Monza, Lombardia : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Monza, Lombardia : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Napoli : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Napoli : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Novara : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Novara : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Orbassano (TO), Piemonte : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Orbassano (TO), Piemonte : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Padova : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Padova : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Palermo, Sicilia : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Palermo, Sicilia : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Parma : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Parma : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Perugia : Azienda Ospedaliera Di Perugia

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Perugia : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Perugia : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Perugia : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Pisa : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Pisa : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Ravenna : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Ravenna : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Roma : A.O San Camillo - Forlanini

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Roma : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Roma : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Roma : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Rozzano (MI), Lombardia : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Rozzano (MI), Lombardia : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Siena : Policlinico Santa Maria Alle Scotte

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Sora : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Torino : Univ. Of Turin, Azienda Ospedaliera S. Luigi Gonzaga

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Torino : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Torino : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Udine : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Udine : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Japan

Aichi : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Aichi : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Chiba : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Chiba : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Fukuoka : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Fukuoka : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Hyogo : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Hyogo : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Kanagawa : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Kanagawa : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Niigata : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Niigata : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Osaka : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Osaka : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Shizuoka : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Shizuoka : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Tokyo : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Tokyo : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Korea

Gyeonggi-do : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Gyeonggi-do : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Seoul : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Seoul : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Netherlands

Amsterdam : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

HARDERWIJK : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

HARDERWIJK : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

HEERLEN : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

HEERLEN : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Helmond : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

NIEUWEGEIN : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

NIEUWEGEIN : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Rotterdam : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Norway

Oslo : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Oslo : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Poland

Bialystok : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Bialystok : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Bystra : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Checiny : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Checiny : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Gdansk : Klinika Onkologii I Radioterapii Akademickie Cent. Kliniczne

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Gdansk : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Gdansk : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Gdansk : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Krakow : Oddzial Onkologii Klinicznej

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Krakow : Klinika Nowotworow Ukladowych

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Krakow : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Krakow : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Kraków : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Lublin : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Olsztyn : Oddzial Chemioterapii

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Poznan : Oddzial Onkologii Klinicznej

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Poznan : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Poznan : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Prabuty : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Szczecin : Oddzial Chemioterapii

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Wodzislaw Slaski : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Zakopane : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Zakopane : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Russia

St. Petersberg : N. N. Petrov Institute of Oncology

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Russian Federation

Arkhangelsk : State Institution Of Healthcare

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Chelyabinsk : Chelyabinsk Regional Oncology Dispensary

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Ivanovo : Ivanovo Regional Oncology Dispensary

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Kazan : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Kazan : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Lipetsk : Lipetsk Regional Oncology Dispensary

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Lipetsk : Municipal Institute Of Healthcare

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Moscow : City Clinical Hospital #57

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Moscow : Research Institute Of Oncology

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Moscow : Cancer Research Centre Rams

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Moscow : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Moscow : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Pyatigorsk : Stavropol Territory Clinical Oncologic Dispensary

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Saint-Petersburg : City Psychoneurological Dispensary #7 With Hospital

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

St. Petersburg : City Clinical Oncology Dispensary, Chest Departmen

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

St. Petersburg : Leningrad Regional Clinical Hospital

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

St. Petersburg : Russian Military Medical Academy

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

St. Petersburg : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

St. Petersburg : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Tomsk : Scientific Research Center For Oncology

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Scotland

Edinburgh : University of Edinburgh, Division of Onclogy

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Singapore

Singapore : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Singapore : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Spain

Badalona. Barcelona : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Barcelona : Research Site:

A Study of Risk Stratification in Patients With Suspected Lung Cancer.

Barcelona : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Barcelona : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Lerida : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Lerida : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

L'Hospitalet de Llobregat : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Madrid : Merck

An Open Label, Randomized Phase I/IIa Trial Evaluating MK0646 in Combination With Erlotinib for Patients With Recurrent Non-Small Cell Lung Cancer

Madrid : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Madrid : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Madrid : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Malaga : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Manresa : Research Site:

A Study of Risk Stratification in Patients With Suspected Lung Cancer.

Oviedo : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Oviedo : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

San Sebastian : Research Site:

A Study of Risk Stratification in Patients With Suspected Lung Cancer.

Santander : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Santander : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Santiago : Research Site:

A Study of Risk Stratification in Patients With Suspected Lung Cancer.

Sevilla : Research Site:

A Study of Risk Stratification in Patients With Suspected Lung Cancer.

Sevilla : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Sevilla : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Valencia : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Valencia : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Valencia : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Sweden

LUND : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

LUND : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

STOCKHOLM : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

STOCKHOLM : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

UPPSALA : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

UPPSALA : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Switerland

Bruderholz : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Switzerland

Aarau : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Bern : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Bern : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Bruderholz : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Chur : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Thun : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Thun : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Zuerich : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Zuerich : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Zürich : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Taiwan

Taichung : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Taichung : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Taipei : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Taipei : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Thailand

Bangkok : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Bangkok : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Chiang Mai : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Chiang Mai : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Ukraine

Dnipropetrovsk : City Clinical Hospital #4

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Donetsk : Regional Antineoplastic Center

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Kharkov : Regional Pediatric Hospital #1

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Kharkov : Regional Clinical Oncology Dispensary

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Kiev : City Oncology Hospital

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Lviv : Lviv State Oncology Regional Treatment And Diagnostic Centre

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Ternopol : Ternopil State Medical University

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

Uzhgorod : Regional Oncology Clinical Dispensary

A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer

United Kingdom

Aberdeen : Aberdeen Royal Infirmary

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Aberdeen : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Aberdeen : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Bebington, Wirral : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Bebington, Wirral : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Belfast : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Belfast : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Cambridge : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Cambridge : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Cambridge : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Cambridge : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Dundee : Division of Cancer Medicine, Biomedical Research Centre

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Dundee : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Dundee : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Edinburgh : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Edinburgh : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Edinburgh : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Glasgow : Department of Medical Oncology

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Glasgow : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Inverness : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Inverness : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Leeds : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Leeds : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Leicester : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Leicester : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

London : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

London : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Maidstone : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Maidstone : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Manchester : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Newcastle upon Tyne : Department of Medical Oncology

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Sheffield : Department of Oncology

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Sheffield : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Sheffield : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Surrey : Celgene Corporation

Patients with small cell lung cancer whose cancer has recurred or progressed during or after having received chemotherapy with a regimen that includes either carboplatin or cisplatin are eligible for the study.

Sutton, Surrey : Department of Medicine

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Sutton, Surrey : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Sutton, Surrey : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).

Wythenshawe : Research Center

MAGRIT est une étude clinique de Phase III qui consiste à évaluer l’utilisation d’une immunothérapie anticancéreuse potentielle (aussi connue sous le nom de vaccin thérapeutique) dans le traitement des patients atteints du cancer du poumon non à petites cellules (NSCLC).

Wythenshawe : Research Center

MAGRIT is a Phase III clinical study which evaluates the use of a potential new immunotherapy (also called a therapeutic vaccine) in the treatment of Non-Small Cell Lung Cancer (NSCLC).